Marker Therapeutics (NASDAQ:MRKR) Releases Earnings Results, Beats Estimates By $0.16 EPS

Marker Therapeutics (NASDAQ:MRKR) announced its quarterly earnings results on Friday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.16, Zacks reports. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%.

Marker Therapeutics Price Performance

Shares of NASDAQ:MRKR traded up $0.03 on Friday, reaching $1.14. The company’s stock had a trading volume of 45,559 shares, compared to its average volume of 164,618. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $2.46. The stock has a market capitalization of $19.00 million, a P/E ratio of -1.87 and a beta of 1.50. The stock’s 50-day moving average is $1.33 and its two-hundred day moving average is $1.43.

Institutional Trading of Marker Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. grew its stake in shares of Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after purchasing an additional 13,340 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Marker Therapeutics by 16.4% during the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Marker Therapeutics during the second quarter worth approximately $33,000. LPL Financial LLC lifted its holdings in shares of Marker Therapeutics by 41.7% during the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after purchasing an additional 24,500 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Marker Therapeutics during the third quarter worth $25,000. 22.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on MRKR shares. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a research report on Wednesday, May 20th. Weiss Ratings cut Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.